Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression

European Journal of Haematology

Volumn 72, Issue 6, 2004, Pages 410-415

  Panteli, K ^a,b   Zagorianakou, N ^a   Bai, M ^a   Katsaraki, A ^a   Agnantis, N J ^a   Bourantas, K ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b NONE   (Greece)

Author keywords

Angiogenesis; CD34; Myeloproliferative diseases

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTHEMIA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BONE MARROW; BONE MARROW EXAMINATION; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDERS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2542523024     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00235.x     Document Type: Article

References (33)

1. FOLKMAN J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
2. FOLKMAN J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
3. BERTOLINI F, MANCUSO P, GOBBI A, PRUNERI G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol 2000;28:99-100.
4. MANGI MH. Review. Angiogenesis and angiogenic mediators in hematological malignancies. Br J Haematol 2000;111:43-51.
5. SINGHAL S, MEHTA J, DESIKAN R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
6. ELLIOT MA, MESA RA, LI C-Y, HOOK C, ANSELL SM, LEVITT RM, GEYER SM, TEFFERI A. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117:288-296.
7. PICCALUGA PP, VISANI G, PILERI SA, et al. Clinical efficasy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16:1609-1614.
8. VERMEULEN PB, GASPARINI G, FOX SB, et al. Quantification of angiogenesis in solid human tumors: an International Consensus on the Methodology and Criteria of Evaluation. Eur J Cancer 1996;32A:2474-2484.
9. TEFFERI A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
10. ROZMAN C, GIRALT M, FELIU E, RUBIO D, CORTES MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663.
11. DUPRIEZ B, MOREL P, DEMORY JL, LAI JL, SIMON M, PLANTIER I, BAUTERS F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-1018.
12. CERVANTES F, PEREIRA A, ESTEVE J, COBO F, ROZMAN C, MONTSERRAT E. Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997;97:635-640.
13. REILLY JT, SNOWDEN JA, SPEARING RL, FITZGERALD PM, JONES N, WATMORE A, POTTER A. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997;98:96-102.
14. REILLY JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997;11:233-242.
15. BOURANTAS KL, TSIARA S, CHRISTOU L, REPOUSIS P, KONSTANTINIDOU P, BAI M, SEFERIADIS K. Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony stimulating factor in idiopathic myelofibrosis. Acta Haematol 1996;96:79-82.
16. MARTYRE MC, ROMQUIN N, LE BOUSSE-KERDILES MC, CHEVILLARD S, BENYAHIA B, DUPRIEZ B, DEMORY JL, BAUTERS F. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16.
17. MARTYRE MC, LE BOUSSE-KERDILES MC, ROMQUIN N, CHEVILLARD S, PRALORAN V, DEMORY J-L, DUPRIEZ B. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441-448.
18. LE BOUSSE-KERDILES MC, MARTYRE MC, the Members of the French INSERM Research Network on Idiopathic Myelofibrosis. Involvement of the fibrogenic cytokines, TGF-β and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol 2001;49:153-157.
19. CHOU JM, LI CY, TEFFERI A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk Res 2003;27:499-504.
20. MOLICA S, SANTORO R, IULIANO F, Di RAIMONDO F, FICHERA E, GIUSTOLISI R. Serum levels of vascular endothelial growth factor in chronic leukemias. A comparative study with emphasis on myeloproliferative disorders. Haematologica 2001;86:771.
21. DI RAIMONDO F, AZZARO MP, PALUMBO GA, BAGNATO S, STAGNO F, GIUSTOLISI GM, CACCIOLA E, SORTINO G, GUGLIELMO P, GIUSTOLISI R. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001;15:976-980.
22. MUSOLINO C, CALABRO L, BELLOMO G, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2001;69:159-163.
23. MESA RA, HANSON CA, RAJKUMAR V, SCHROEDER G, TEFFERI A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-3380.
24. LUNDBERG LG, LERNER R, SUNDELIN P, ROGERS R, FOLKMAN J, PALMBLAD J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-19.
25. PRUNERI G, BERTOLINI F, SOLIGO D, CARBONI N, CORTELEZZI A, FERRUCCI PF, BUFFA R, Lambertenghi-Deliliers and Pezzella F. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-1401.
26. AQUAYO A, KANTARGIAN H, MANSHOURI T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
27. KORKOPOULOU P, VINIOU N, KAVANTZAS N, et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003;17:89-97.
28. MESA RA, HANSON CA, LI C-Y, YOON S-Y, RAJKUMAR SV, SCHROEDER G, TEFFERI A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002;99:4131-4137.
29. MURPHY P, AHMED N, HASSAN HT. Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera. Leuk Res 2002; 26:1007-1010.
30. BAROSI G, AMBROSETTI A, FINELLI C, et al. FOR THE ICSG ON MMM. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999;104:730-737.
31. RUPOLI S, DA LIO L, SISTI S, CAMPANATI G, SALVI A, BRIANZONI MF, D'AMICO S, CINCIRIPINI A, LEONI P. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994;68:205-212.
32. PUGH CW, RATCLIFFE PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med 2003;9:677-684.
33. FERRARA N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-543.